Industry Research Reports

Home > Reports > Pharma & Healthcare > DTaP and Tdap Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

DTaP and Tdap Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published Date: 2024-01-24

Pages: 124 Pages

Report ld: 2331225

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.

Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.

The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.

The global market for DTaP and Tdap Vaccines was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

MARKET SEGMENTATION

By Company

Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

DTaP
Td
Tdap

Segment by Application

Adult
Pediatric

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for DTaP and Tdap Vaccines, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of DTaP and Tdap Vaccines by region & country, by Type, and by Application.

The DTaP and Tdap Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DTaP and Tdap Vaccines.

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of DTaP and Tdap Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of DTaP and Tdap Vaccines in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 DTaP and Tdap Vaccines Product Introduction

1.2 Global DTaP and Tdap Vaccines Market Size Forecast

1.2.1 Global DTaP and Tdap Vaccines Sales Value (2019-2030)

1.2.2 Global DTaP and Tdap Vaccines Sales Volume (2019-2030)

1.2.3 Global DTaP and Tdap Vaccines Sales Price (2019-2030)

1.3 DTaP and Tdap Vaccines Market Trends & Drivers

1.3.1 DTaP and Tdap Vaccines Industry Trends

1.3.2 DTaP and Tdap Vaccines Market Drivers & Opportunity

1.3.3 DTaP and Tdap Vaccines Market Challenges

1.3.4 DTaP and Tdap Vaccines Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global DTaP and Tdap Vaccines Players Revenue Ranking (2023)

2.2 Global DTaP and Tdap Vaccines Revenue by Company (2019-2024)

2.3 Global DTaP and Tdap Vaccines Players Sales Volume Ranking (2023)

2.4 Global DTaP and Tdap Vaccines Sales Volume by Company Players (2019-2024)

2.5 Global DTaP and Tdap Vaccines Average Price by Company (2019-2024)

2.6 Key Manufacturers DTaP and Tdap Vaccines Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers DTaP and Tdap Vaccines Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of DTaP and Tdap Vaccines

2.9 DTaP and Tdap Vaccines Market Competitive Analysis

2.9.1 DTaP and Tdap Vaccines Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by DTaP and Tdap Vaccines Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DTaP and Tdap Vaccines as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 DTaP

3.1.2 Td

3.1.3 Tdap

3.2 Global DTaP and Tdap Vaccines Sales Value by Type

3.2.1 Global DTaP and Tdap Vaccines Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global DTaP and Tdap Vaccines Sales Value, by Type (2019-2030)

3.2.3 Global DTaP and Tdap Vaccines Sales Value, by Type (%) (2019-2030)

3.3 Global DTaP and Tdap Vaccines Sales Volume by Type

3.3.1 Global DTaP and Tdap Vaccines Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global DTaP and Tdap Vaccines Sales Volume, by Type (2019-2030)

3.3.3 Global DTaP and Tdap Vaccines Sales Volume, by Type (%) (2019-2030)

3.4 Global DTaP and Tdap Vaccines Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Adult

4.1.2 Pediatric

4.2 Global DTaP and Tdap Vaccines Sales Value by Application

4.2.1 Global DTaP and Tdap Vaccines Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global DTaP and Tdap Vaccines Sales Value, by Application (2019-2030)

4.2.3 Global DTaP and Tdap Vaccines Sales Value, by Application (%) (2019-2030)

4.3 Global DTaP and Tdap Vaccines Sales Volume by Application

4.3.1 Global DTaP and Tdap Vaccines Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global DTaP and Tdap Vaccines Sales Volume, by Application (2019-2030)

4.3.3 Global DTaP and Tdap Vaccines Sales Volume, by Application (%) (2019-2030)

4.4 Global DTaP and Tdap Vaccines Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global DTaP and Tdap Vaccines Sales Value by Region

5.1.1 Global DTaP and Tdap Vaccines Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global DTaP and Tdap Vaccines Sales Value by Region (2019-2024)

5.1.3 Global DTaP and Tdap Vaccines Sales Value by Region (2025-2030)

5.1.4 Global DTaP and Tdap Vaccines Sales Value by Region (%), (2019-2030)

5.2 Global DTaP and Tdap Vaccines Sales Volume by Region

5.2.1 Global DTaP and Tdap Vaccines Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global DTaP and Tdap Vaccines Sales Volume by Region (2019-2024)

5.2.3 Global DTaP and Tdap Vaccines Sales Volume by Region (2025-2030)

5.2.4 Global DTaP and Tdap Vaccines Sales Volume by Region (%), (2019-2030)

5.3 Global DTaP and Tdap Vaccines Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America DTaP and Tdap Vaccines Sales Value, 2019-2030

5.4.2 North America DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe DTaP and Tdap Vaccines Sales Value, 2019-2030

5.5.2 Europe DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific DTaP and Tdap Vaccines Sales Value, 2019-2030

5.6.2 Asia Pacific DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America DTaP and Tdap Vaccines Sales Value, 2019-2030

5.7.2 South America DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa DTaP and Tdap Vaccines Sales Value, 2019-2030

5.8.2 Middle East & Africa DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions DTaP and Tdap Vaccines Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions DTaP and Tdap Vaccines Sales Value

6.2.1 Key Countries/Regions DTaP and Tdap Vaccines Sales Value, 2019-2030

6.2.2 Key Countries/Regions DTaP and Tdap Vaccines Sales Volume, 2019-2030

6.3 United States

6.3.1 United States DTaP and Tdap Vaccines Sales Value, 2019-2030

6.3.2 United States DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

6.3.3 United States DTaP and Tdap Vaccines Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe DTaP and Tdap Vaccines Sales Value, 2019-2030

6.4.2 Europe DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe DTaP and Tdap Vaccines Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China DTaP and Tdap Vaccines Sales Value, 2019-2030

6.5.2 China DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

6.5.3 China DTaP and Tdap Vaccines Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan DTaP and Tdap Vaccines Sales Value, 2019-2030

6.6.2 Japan DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan DTaP and Tdap Vaccines Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea DTaP and Tdap Vaccines Sales Value, 2019-2030

6.7.2 South Korea DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea DTaP and Tdap Vaccines Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia DTaP and Tdap Vaccines Sales Value, 2019-2030

6.8.2 Southeast Asia DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia DTaP and Tdap Vaccines Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India DTaP and Tdap Vaccines Sales Value, 2019-2030

6.9.2 India DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

6.9.3 India DTaP and Tdap Vaccines Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Sanofi Pasteur

7.1.1 Sanofi Pasteur Company Information

7.1.2 Sanofi Pasteur Introduction and Business Overview

7.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Product Offerings

7.1.5 Sanofi Pasteur Recent Development

7.2 GlaxoSmithKline

7.2.1 GlaxoSmithKline Company Information

7.2.2 GlaxoSmithKline Introduction and Business Overview

7.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Product Offerings

7.2.5 GlaxoSmithKline Recent Development

7.3 Protein Sciences Corporation

7.3.1 Protein Sciences Corporation Company Information

7.3.2 Protein Sciences Corporation Introduction and Business Overview

7.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Product Offerings

7.3.5 Protein Sciences Corporation Recent Development

7.4 Novartis AG

7.4.1 Novartis AG Company Information

7.4.2 Novartis AG Introduction and Business Overview

7.4.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Novartis AG DTaP and Tdap Vaccines Product Offerings

7.4.5 Novartis AG Recent Development

7.5 Seqirus

7.5.1 Seqirus Company Information

7.5.2 Seqirus Introduction and Business Overview

7.5.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Seqirus DTaP and Tdap Vaccines Product Offerings

7.5.5 Seqirus Recent Development

7.6 Merck Sharp & Dohme Corp

7.6.1 Merck Sharp & Dohme Corp Company Information

7.6.2 Merck Sharp & Dohme Corp Introduction and Business Overview

7.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Offerings

7.6.5 Merck Sharp & Dohme Corp Recent Development

7.7 Astellas Pharma US, Inc

7.7.1 Astellas Pharma US, Inc Company Information

7.7.2 Astellas Pharma US, Inc Introduction and Business Overview

7.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Offerings

7.7.5 Astellas Pharma US, Inc Recent Development

7.8 Pfizer Inc

7.8.1 Pfizer Inc Company Information

7.8.2 Pfizer Inc Introduction and Business Overview

7.8.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Pfizer Inc DTaP and Tdap Vaccines Product Offerings

7.8.5 Pfizer Inc Recent Development

7.9 Johnson & Johnson

7.9.1 Johnson & Johnson Company Information

7.9.2 Johnson & Johnson Introduction and Business Overview

7.9.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Johnson & Johnson DTaP and Tdap Vaccines Product Offerings

7.9.5 Johnson & Johnson Recent Development

7.10 Lanzhou Institute of Biological Products Co., Ltd

7.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information

7.10.2 Lanzhou Institute of Biological Products Co., Ltd Introduction and Business Overview

7.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Offerings

7.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Development

7.11 AstraZeneca

7.11.1 AstraZeneca Company Information

7.11.2 AstraZeneca Introduction and Business Overview

7.11.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.11.4 AstraZeneca DTaP and Tdap Vaccines Product Offerings

7.11.5 AstraZeneca Recent Development

7.12 Emergent BioSolutions Inc

7.12.1 Emergent BioSolutions Inc Company Information

7.12.2 Emergent BioSolutions Inc Introduction and Business Overview

7.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2019-2024)

7.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Offerings

7.12.5 Emergent BioSolutions Inc Recent Development

8 Industry Chain Analysis

8.1 DTaP and Tdap Vaccines Industrial Chain

8.2 DTaP and Tdap Vaccines Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 DTaP and Tdap Vaccines Sales Model

8.5.2 Sales Channel

8.5.3 DTaP and Tdap Vaccines Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. DTaP and Tdap Vaccines Market Trends

Table 2. DTaP and Tdap Vaccines Market Drivers & Opportunity

Table 3. DTaP and Tdap Vaccines Market Challenges

Table 4. DTaP and Tdap Vaccines Market Restraints

Table 5. Global DTaP and Tdap Vaccines Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global DTaP and Tdap Vaccines Revenue Market Share by Company (2019-2024)

Table 7. Global DTaP and Tdap Vaccines Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global DTaP and Tdap Vaccines Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market DTaP and Tdap Vaccines Price by Company (2019-2024) & (USD/Unit)

Table 10. Key Manufacturers DTaP and Tdap Vaccines Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers DTaP and Tdap Vaccines Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of DTaP and Tdap Vaccines

Table 13. Global DTaP and Tdap Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DTaP and Tdap Vaccines as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global DTaP and Tdap Vaccines Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global DTaP and Tdap Vaccines Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global DTaP and Tdap Vaccines Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global DTaP and Tdap Vaccines Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global DTaP and Tdap Vaccines Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global DTaP and Tdap Vaccines Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global DTaP and Tdap Vaccines Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global DTaP and Tdap Vaccines Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global DTaP and Tdap Vaccines Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global DTaP and Tdap Vaccines Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global DTaP and Tdap Vaccines Price by Type (2019-2024) & (USD/Unit)

Table 27. Global DTaP and Tdap Vaccines Price by Type (2025-2030) & (USD/Unit)

Table 28. Global DTaP and Tdap Vaccines Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global DTaP and Tdap Vaccines Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global DTaP and Tdap Vaccines Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global DTaP and Tdap Vaccines Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global DTaP and Tdap Vaccines Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global DTaP and Tdap Vaccines Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global DTaP and Tdap Vaccines Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global DTaP and Tdap Vaccines Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global DTaP and Tdap Vaccines Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global DTaP and Tdap Vaccines Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global DTaP and Tdap Vaccines Price by Application (2019-2024) & (USD/Unit)

Table 39. Global DTaP and Tdap Vaccines Price by Application (2025-2030) & (USD/Unit)

Table 40. Global DTaP and Tdap Vaccines Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global DTaP and Tdap Vaccines Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global DTaP and Tdap Vaccines Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global DTaP and Tdap Vaccines Sales Value by Region (2019-2024) & (%)

Table 44. Global DTaP and Tdap Vaccines Sales Value by Region (2025-2030) & (%)

Table 45. Global DTaP and Tdap Vaccines Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global DTaP and Tdap Vaccines Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global DTaP and Tdap Vaccines Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global DTaP and Tdap Vaccines Sales Volume by Region (2019-2024) & (%)

Table 49. Global DTaP and Tdap Vaccines Sales Volume by Region (2025-2030) & (%)

Table 50. Global DTaP and Tdap Vaccines Average Price by Region (2019-2024) & (USD/Unit)

Table 51. Global DTaP and Tdap Vaccines Average Price by Region (2025-2030) & (USD/Unit)

Table 52. Key Countries/Regions DTaP and Tdap Vaccines Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions DTaP and Tdap Vaccines Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions DTaP and Tdap Vaccines Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions DTaP and Tdap Vaccines Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions DTaP and Tdap Vaccines Sales Volume, (2025-2030) & (K Units)

Table 57. Sanofi Pasteur Company Information

Table 58. Sanofi Pasteur Introduction and Business Overview

Table 59. Sanofi Pasteur DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 60. Sanofi Pasteur DTaP and Tdap Vaccines Product Offerings

Table 61. Sanofi Pasteur Recent Development

Table 62. GlaxoSmithKline Company Information

Table 63. GlaxoSmithKline Introduction and Business Overview

Table 64. GlaxoSmithKline DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 65. GlaxoSmithKline DTaP and Tdap Vaccines Product Offerings

Table 66. GlaxoSmithKline Recent Development

Table 67. Protein Sciences Corporation Company Information

Table 68. Protein Sciences Corporation Introduction and Business Overview

Table 69. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 70. Protein Sciences Corporation DTaP and Tdap Vaccines Product Offerings

Table 71. Protein Sciences Corporation Recent Development

Table 72. Novartis AG Company Information

Table 73. Novartis AG Introduction and Business Overview

Table 74. Novartis AG DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 75. Novartis AG DTaP and Tdap Vaccines Product Offerings

Table 76. Novartis AG Recent Development

Table 77. Seqirus Company Information

Table 78. Seqirus Introduction and Business Overview

Table 79. Seqirus DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 80. Seqirus DTaP and Tdap Vaccines Product Offerings

Table 81. Seqirus Recent Development

Table 82. Merck Sharp & Dohme Corp Company Information

Table 83. Merck Sharp & Dohme Corp Introduction and Business Overview

Table 84. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 85. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Offerings

Table 86. Merck Sharp & Dohme Corp Recent Development

Table 87. Astellas Pharma US, Inc Company Information

Table 88. Astellas Pharma US, Inc Introduction and Business Overview

Table 89. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 90. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Offerings

Table 91. Astellas Pharma US, Inc Recent Development

Table 92. Pfizer Inc Company Information

Table 93. Pfizer Inc Introduction and Business Overview

Table 94. Pfizer Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 95. Pfizer Inc DTaP and Tdap Vaccines Product Offerings

Table 96. Pfizer Inc Recent Development

Table 97. Johnson & Johnson Company Information

Table 98. Johnson & Johnson Introduction and Business Overview

Table 99. Johnson & Johnson DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 100. Johnson & Johnson DTaP and Tdap Vaccines Product Offerings

Table 101. Johnson & Johnson Recent Development

Table 102. Lanzhou Institute of Biological Products Co., Ltd Company Information

Table 103. Lanzhou Institute of Biological Products Co., Ltd Introduction and Business Overview

Table 104. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 105. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Offerings

Table 106. Lanzhou Institute of Biological Products Co., Ltd Recent Development

Table 107. AstraZeneca Company Information

Table 108. AstraZeneca Introduction and Business Overview

Table 109. AstraZeneca DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 110. AstraZeneca DTaP and Tdap Vaccines Product Offerings

Table 111. AstraZeneca Recent Development

Table 112. Emergent BioSolutions Inc Company Information

Table 113. Emergent BioSolutions Inc Introduction and Business Overview

Table 114. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 115. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Offerings

Table 116. Emergent BioSolutions Inc Recent Development

Table 117. Key Raw Materials Lists

Table 118. Raw Materials Key Suppliers Lists

Table 119. DTaP and Tdap Vaccines Downstream Customers

Table 120. DTaP and Tdap Vaccines Distributors List

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

List of Figures

Figure 1. DTaP and Tdap Vaccines Product Picture

Figure 2. Global DTaP and Tdap Vaccines Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global DTaP and Tdap Vaccines Sales Value (2019-2030) & (US$ Million)

Figure 4. Global DTaP and Tdap Vaccines Sales Volume (2019-2030) & (K Units)

Figure 5. Global DTaP and Tdap Vaccines Sales Price (2019-2030) & (USD/Unit)

Figure 6. DTaP and Tdap Vaccines Report Years Considered

Figure 7. Global DTaP and Tdap Vaccines Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global DTaP and Tdap Vaccines Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by DTaP and Tdap Vaccines Revenue in 2023

Figure 10. DTaP and Tdap Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. DTaP Picture

Figure 12. Td Picture

Figure 13. Tdap Picture

Figure 14. Global DTaP and Tdap Vaccines Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global DTaP and Tdap Vaccines Sales Value Market Share by Type, 2023 & 2030

Figure 16. Global DTaP and Tdap Vaccines Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 17. Global DTaP and Tdap Vaccines Sales Volume Market Share by Type, 2023 & 2030

Figure 18. Global DTaP and Tdap Vaccines Price by Type (2019-2030) & (USD/Unit)

Figure 19. Product Picture of Adult

Figure 20. Product Picture of Pediatric

Figure 21. Global DTaP and Tdap Vaccines Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 22. Global DTaP and Tdap Vaccines Sales Value Market Share by Application, 2023 & 2030

Figure 23. Global DTaP and Tdap Vaccines Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 24. Global DTaP and Tdap Vaccines Sales Volume Market Share by Application, 2023 & 2030

Figure 25. Global DTaP and Tdap Vaccines Price by Application (2019-2030) & (USD/Unit)

Figure 26. North America DTaP and Tdap Vaccines Sales Value (2019-2030) & (US$ Million)

Figure 27. North America DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

Figure 28. Europe DTaP and Tdap Vaccines Sales Value (2019-2030) & (US$ Million)

Figure 29. Europe DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

Figure 30. Asia Pacific DTaP and Tdap Vaccines Sales Value (2019-2030) & (US$ Million)

Figure 31. Asia Pacific DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

Figure 32. South America DTaP and Tdap Vaccines Sales Value (2019-2030) & (US$ Million)

Figure 33. South America DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

Figure 34. Middle East & Africa DTaP and Tdap Vaccines Sales Value (2019-2030) & (US$ Million)

Figure 35. Middle East & Africa DTaP and Tdap Vaccines Sales Value by Country (%), 2023 VS 2030

Figure 36. Key Countries/Regions DTaP and Tdap Vaccines Sales Value (%), (2019-2030)

Figure 37. Key Countries/Regions DTaP and Tdap Vaccines Sales Volume (%), (2019-2030)

Figure 38. United States DTaP and Tdap Vaccines Sales Value, (2019-2030) & (US$ Million)

Figure 39. United States DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

Figure 40. United States DTaP and Tdap Vaccines Sales Value by Application (%), 2023 VS 2030

Figure 41. Europe DTaP and Tdap Vaccines Sales Value, (2019-2030) & (US$ Million)

Figure 42. Europe DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

Figure 43. Europe DTaP and Tdap Vaccines Sales Value by Application (%), 2023 VS 2030

Figure 44. China DTaP and Tdap Vaccines Sales Value, (2019-2030) & (US$ Million)

Figure 45. China DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

Figure 46. China DTaP and Tdap Vaccines Sales Value by Application (%), 2023 VS 2030

Figure 47. Japan DTaP and Tdap Vaccines Sales Value, (2019-2030) & (US$ Million)

Figure 48. Japan DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

Figure 49. Japan DTaP and Tdap Vaccines Sales Value by Application (%), 2023 VS 2030

Figure 50. South Korea DTaP and Tdap Vaccines Sales Value, (2019-2030) & (US$ Million)

Figure 51. South Korea DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

Figure 52. South Korea DTaP and Tdap Vaccines Sales Value by Application (%), 2023 VS 2030

Figure 53. Southeast Asia DTaP and Tdap Vaccines Sales Value, (2019-2030) & (US$ Million)

Figure 54. Southeast Asia DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

Figure 55. Southeast Asia DTaP and Tdap Vaccines Sales Value by Application (%), 2023 VS 2030

Figure 56. India DTaP and Tdap Vaccines Sales Value, (2019-2030) & (US$ Million)

Figure 57. India DTaP and Tdap Vaccines Sales Value by Type (%), 2023 VS 2030

Figure 58. India DTaP and Tdap Vaccines Sales Value by Application (%), 2023 VS 2030

Figure 59. DTaP and Tdap Vaccines Industrial Chain

Figure 60. DTaP and Tdap Vaccines Manufacturing Cost Structure

Figure 61. Channels of Distribution (Direct Sales, and Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global DTaP and Tdap Vaccines market? zhanKai

The top companies in the global DTaP and Tdap Vaccines market are Sanofi Pasteur、GlaxoSmithKline、Protein Sciences Corporation.

Related Reports

DTaP and Tdap Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for DTaP and Tdap Vaccines was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-07-15
Pages: 137
USD 3950.00
(Single User License)
Global DTaP and Tdap Vaccines Market Research Report 2026
The global DTaP and Tdap Vaccines market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-04-28
Pages: 123
USD 2900.00
(Single User License)
Global DTaP and Tdap Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global DTaP and Tdap Vaccines market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 97
USD 4250.00
(Single User License)
DTaP and Tdap Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for DTaP and Tdap Vaccines was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 116
USD 3950.00
(Single User License)
Global DTaP and Tdap Vaccines Market Research Report 2025
The global market for DTaP and Tdap Vaccines was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-25
Pages: 96
USD 2900.00
(Single User License)
Global DTaP and Tdap Vaccines Market Insights, Forecast to 2030
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.
Published Date: 2024-04-15
Pages: 111
USD 4900.00
(Single User License)
Global DTaP and Tdap Vaccines Market Research Report 2024
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.
Published Date: 2024-01-16
Pages: 89
USD 2900.00
(Single User License)

DTaP and Tdap Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for DTaP and Tdap Vaccines was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-07-15
Pages: 137
USD 3950.00 (Single User License)
Global DTaP and Tdap Vaccines Market Research Report 2026
The global DTaP and Tdap Vaccines market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-04-28
Pages: 123
USD 2900.00 (Single User License)
Global DTaP and Tdap Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global DTaP and Tdap Vaccines market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 97
USD 4250.00 (Single User License)
DTaP and Tdap Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for DTaP and Tdap Vaccines was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 116
USD 3950.00 (Single User License)
Global DTaP and Tdap Vaccines Market Research Report 2025
The global market for DTaP and Tdap Vaccines was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-25
Pages: 96
USD 2900.00 (Single User License)
Global DTaP and Tdap Vaccines Market Insights, Forecast to 2030
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.
Published: 2024-04-15
Pages: 111
USD 4900.00 (Single User License)
Global DTaP and Tdap Vaccines Market Research Report 2024
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.
Published: 2024-01-16
Pages: 89
USD 2900.00 (Single User License)